NCT07096986View on ClinicalTrials.gov

Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Glomerulonephritis

Interventions

DRUG

Forxiga

dapagliflozin treatment at a dose of 10 mg per os daily for 6 months

Trial Locations (1)

Unknown

CHU de NICE, Nice

All Listed Sponsors

lead

Centre Hospitalier Universitaire de Nice

OTHER